All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Genome-wide association studies (GWAS) have been highly successful in identifying common genomic variants that are associated with complex human diseases or traits. However, these common variants have small effects, and in aggregate explain only a small fraction of heritability for most diseases or traits. The major portion of heritability remains missing, and this represents a major dilemma in complex trait genetics referred to as "missing heritability". Gene-gene interaction has been proposed to be a contributor to the problem of missing heritability.

Gene-gene interaction has been long known to have an impact on an organism's phenotype, for example, the color of a flower in plants and the color of a fly's eye. However, it has been challenging to detect gene-gene interaction in human GWAS. Moreover, no gene interaction was functionally validated. Considering the potentially large number of gene-gene interaction, identification of true and casual interaction has been proven to be a daunting task. However, without doubt, studies of gene-gene interaction will contribute to the understanding of inheritance, particularly inheritance of important diseases and traits, and provide insights into the biological pathways and molecular mechanisms of disease pathogenesis.

Atrial fibrillation (AF) is the most common cardiac arrhythmia seen at the clinical setting and accounts for approximately one-third of hospitalizations for cardiac rhythm disturbances \[[@pgen.1005393.ref001]\]. The prevalence of AF is 0.4%-1.0% in the general population, and increases with age, reaching 8% in people over 80 \[[@pgen.1005393.ref001]\]. A similar prevalence rate of 0.77% was found for AF in the Chinese population \[[@pgen.1005393.ref002]\]. AF accounts for 15% of all strokes, worsens heart failure, and independently increases the risk of stroke 5-fold and risk of cardiac death up to 1.9-fold \[[@pgen.1005393.ref003]\]. Genetic factors play an important role in the pathogenesis of AF. The heritability of polygenic liability to AF has been estimated to be 0.62 \[[@pgen.1005393.ref004]\].

To date, several major GWAS have been reported for common complex AF and identified variants in ten chromosomal loci that were associated with AF. The first GWAS for AF identified significant association between SNP rs2200733 near the *PITX2c* gene encoding paired-like homeodomain 2 transcript c on chromosome 4q25 and AF in several populations of European ancestry as well as one Hong Kong population \[[@pgen.1005393.ref005]\]. Our group later reported that SNP rs2200733 confers a significant risk in the mainland Chinese Han population, too \[[@pgen.1005393.ref006]\]. Then, two independent GWAS identified significant association between AF and SNPs rs2106261 \[[@pgen.1005393.ref007]\] and rs7193343 \[[@pgen.1005393.ref008]\], both of which are located in the *ZFHX3* gene encoding zinc finger homeobox 3 on chromosome 16q22. We have found that rs2106261, but not rs7193343, showed significant association with AF in the Chinese Han population \[[@pgen.1005393.ref009]\]. Later, a common variant in *KCNN3* (encoding potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3), rs13376333, was found to be associated with lone AF \[[@pgen.1005393.ref010]\]. However, we found that rs13376333 did not show significant association with AF in the Chinese Han population \[[@pgen.1005393.ref009]\]. Ellinor et al \[[@pgen.1005393.ref011]\] identified six susceptibility loci for AF through meta-GWAS analysis. We have shown that only one SNP, rs3807989 at the *CAV1* locus (encoding caveolin 1) among the six loci, were associated with AF in the Chinese Han population \[[@pgen.1005393.ref012]\]. In this study, we studied the gene-gene interaction for three AF loci replicated in the Chinese population, i.e. SNP rs2106261 in *ZFHX3*, rs2200733 near *PITX2c*, and rs3807989 in *CAV1*. We provide strong genetic evidence that SNP rs2200733 near *PITX2c* and rs2106261 in *ZFHX3* interact with each other, resulting in a synergistic effect that increases the odds ratios (ORs) to risk of AF. Most importantly, we also carried out a series of cellular and molecular studies to identify the molecular mechanisms underlying the gene--gene interaction. We found that *PITX2c* and *ZFHX3* cross-regulate each other's expression as well as expression of downstream genes such as *NPPA* (encoding atrial natriuretic factor or ANF), providing a novel molecular basis for their interaction at the molecular genetic level.

Results {#sec002}
=======

Significant association between SNP rs2200733 near *PITX2c* on 4q25 and rs2106261 in *ZFHX3* on 16q22 and AF in three independent populations {#sec003}
---------------------------------------------------------------------------------------------------------------------------------------------

We previously reported that among the first three genetic loci for AF identified by GWAS in European ancestry populations, only rs2200733 at the *PITX2c* locus on 4q25 and rs2106261 in *ZFHX3* on 16q22, but not rs13376333 in *KCNN3*, were replicated in the Chinese Han populations \[[@pgen.1005393.ref006],[@pgen.1005393.ref009]\]. We, therefore, carried out a deeper study to determine whether there is gene-gene interaction between rs2200733 and rs2106261. We utilized a case control design which involves three independent populations. The initial association study was carried out with 569 AF patients and 1,996 non-AF control samples (referred to as the Discovery population). The positive findings in the Discovery population were validated in two independent replication populations. The first replication population consisted of 641 AF cases and 1,692 controls (referred to as Replication I population). The second replication population consisted of 810 cases and 1,627 controls (referred to as Replication II population). The clinical characteristics of the three study populations are shown in [S1 Table](#pgen.1005393.s002){ref-type="supplementary-material"}.

We first examined the association of AF with each GWAS SNP individually. There was no deviation from the Hardy-Weinberg equilibrium for the two SNPs, rs2200733 and rs2106261 in the control groups of the three populations ([S2 Table](#pgen.1005393.s003){ref-type="supplementary-material"}).

As shown in [S3 Table](#pgen.1005393.s004){ref-type="supplementary-material"}, SNP rs2200733 showed highly significant association with AF in the Discovery population with a *P* value of 1.58×10^-14^ (OR = 1.70 (95% CI 1.48--1.94)) with the T allele as the risk allele. After adjusting for covariates of age and gender with multivariable logistical regression analysis, rs2200733 remained significantly associated with AF (*Padj* = 5.50×10^-13^, OR = 1.32 (95% CI 1.22--1.42)). SNP rs2200733 remained significant association with AF in Replication I population (*Pobs* = 1.27×^10-11^, OR = 1.57 (95% CI 1.38--1.79); *Padj* = 3.17×10^-10^, OR = 1.27 (95% CI 1.18--1.37)) and Replication II population (*Pobs* = 2.20×10^-10^, OR = 1.48 (95% CI 1.31--1.67); *Padj* = 7.84×10^-10^, OR = 1.22 (95% CI 1.14--1.29)). In the combined population, the association between SNP rs2200733 and AF was highly significant (*Pobs* = 2.83×10^-33^, OR = 1.57 (95% CI 1.46--1.69); *Padj* = 4.54×10^-29^, OR = 1.26 (95% CI 1.21--1.31)). In addition to analysis of allelic association, we also analyzed genotypic association assuming three different genetic models. As shown in [S4 Table](#pgen.1005393.s005){ref-type="supplementary-material"}, highly significant genotypic associations were detected between SNP rs2200733 and AF in the Discovery population, Replication I population and Replication II population in an additive, dominant, or recessive model. In the combined cohort of the three populations, the genotypic associations between SNP rs2200733 and AF were also highly significant with *Padj* of 4.54×10^-29^ (OR = 1.61 (95% CI 1.48--1.75)), 1.82×10^-23^ (OR = 1.36 (95% CI 1.28--1.45)) and 4.69×10^-16^ (OR = 1.37 (95% CI 1.27--1.48)) under an additive, recessive and dominant model, respectively ([S4 Table](#pgen.1005393.s005){ref-type="supplementary-material"}).

Similarly, SNP rs2106261 on 16q22 also showed significant allelic and genotypic association with AF in the Discovery population, Replication I population and Replication II population ([S3](#pgen.1005393.s004){ref-type="supplementary-material"} and [S4](#pgen.1005393.s005){ref-type="supplementary-material"} Tables, respectively). In the combined population, the allelic association between SNP rs2106261 and AF was highly significant (*Pobs* = 6.26×10^-12^, OR = 1.30 (95% CI 1.21--1.40); *Padj* = 3.03×10^-12^, OR = 1.16 (95% CI 1.11--1.21)) ([S3 Table](#pgen.1005393.s004){ref-type="supplementary-material"}) with the A allele as the risk allele. Genotypic associations were also identified between rs2106261 and AF (*Padj* of 3.11×10^-12^ (OR = 1.33 (95% CI 1.23--1.45)), 1.02×10^-12^ (OR = 1.35 (95% CI 1.24--1.46)) and 1.42×10^-6^ (OR = 1.15 (95% CI 1.08--1.21)) under an additive, recessive and dominant model, respectively ([S4 Table](#pgen.1005393.s005){ref-type="supplementary-material"}).

Gene-gene interaction between *ZFHX3* variant rs2106261 and *PITX2c* variant rs2200733 {#sec004}
--------------------------------------------------------------------------------------

To study the interaction between rs2106261 (G to A substitution, risk allele = A) and rs2200733 (C to T substitution, risk allele = T), we first defined the frequencies of nine possible two-locus genotypes (3^2^ genotypes: GGCC, GGCT, GGTT, AGCC, AGCT, AGTT, AACC, AACT, AATT) in cases and controls of the three independent study populations. Then, we used the wild type non-risk GGCC genotype (non-risk homozygote for both loci) as baseline or reference, and estimated the OR for each of the eight other genotypes. As shown in [Table 1](#pgen.1005393.t001){ref-type="table"} and [Fig 1](#pgen.1005393.g001){ref-type="fig"} and [S1 Fig](#pgen.1005393.s001){ref-type="supplementary-material"}, compared with the GGCC non-risk reference genotype, the double risk homozygous genotype AATT showed a dramatically increased risk for AF with the highest ORs of 4.81 (95% CI 2.88--8.04) (*Pobs* = 3.83×10^-10^) and 6.64 (95% CI 3.64--12.11) (*Padj* = 6.38×10^-10^) before and after adjustment for covariates of age and gender, respectively, in the Discovery population. This interesting finding was replicated in two independent AF populations with ORs of 4.04 (95% CI 2.23--7.32) (*Padj* = 4.34×10^-6^, Replication I) and 5.70 (95% CI 3.34--9.71) (*Padj* = 1.58×10^-10^, Replication II). In the combined cohort of the three populations, AATT increased risk of AF with an OR of 5.36 (95% CI 3.87--7.43) (*Padj* = 8.00×10^-24^) ([Table 1](#pgen.1005393.t001){ref-type="table"}).
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###### ORs for 8 two-locus genotypes versus non-risk homozygous genotype GGCC as a reference for SNPs rs2200733 and rs2106261 in the Chinese Han populations.

![](pgen.1005393.t001){#pgen.1005393.t001g}

  Two-locus genotype                                                       Allele test[^a^](#t001fn002){ref-type="table-fn"}   Adjust for age and gender[^b^](#t001fn003){ref-type="table-fn"}                                      
  ----------------------------------------------------- ---- ------------- --------------------------------------------------- ----------------------------------------------------------------- ------------------- -------------- --------------------
  Discovery population 569 cases /1,996 controls                                                                                                                                                                                    
  GG                                                    CC   44 (7.7%)     230 (11.5%)                                         N.A‡                                                              1.00                N.A            1.00
  GG                                                    CT   106 (18.6%)   475 (23.8%)                                         0.43                                                              1.17 (0.79--1.72)   0.34           1.11 (0.89--1.39)
  GG                                                    TT   83 (14.6%)    206 (10.3%)                                         3.27×10^-4^                                                       2.11 (1.40--3.18)   1.0×10^-3^     2.14 (1.36--3.38)
  AG                                                    CC   21 (3.7%)     206 (10.3%)                                         0.02                                                              1.88 (1.08--3.26)   0.10           1.70 (0.92--3.17)
  AG                                                    CT   117 (20.6%)   420 (21.0%)                                         0.05                                                              1.46 (0.99--2.13)   0.02           1.72 (1.11--2.68)
  AG                                                    TT   99 (17.4%)    243 (12.2%)                                         1.66×10^-4^                                                       2.13 (1.43--3.17)   1.66×10^-4^    2.27 (1.45--3.56)
  AA                                                    CC   13 (2.3%)     51 (2.6%)                                           0.41                                                              1.33 (0.67--2.65)   0.31           1.23 (0.83--1.83)
  AA                                                    CT   40 (7.0%)     115 (5.8%)                                          0.02                                                              1.82 (1.12--2.95)   0.03           1.83 (1.06--3.17)
  AA                                                    TT   46 (8.1%)     50 (2.5%)                                           3.83×10^-10^                                                      4.81 (2.88--8.04)   6.38×10^-10^   6.64 (3.64--12.11)
  Replication I population 641 cases /1,692 controls                                                                                                                                                                                
  GG                                                    CC   43 (6.7%)     199 (11.8%)                                         N.A                                                               1.00                N.A            1.00
  GG                                                    CT   129 (20.1%)   413 (24.4%)                                         0.06                                                              1.45 (0.98--2.12)   0.22           1.33 (0.85--2.07)
  GG                                                    TT   87 (13.6%)    176 (10.4%)                                         8.44×10^-5^                                                       2.29 (1.51--3.47)   1.00×10^-3^    2.16 (1.35--3.45)
  AG                                                    CC   44 (6.9%)     166 (9.8%)                                          0.39                                                              1.23 (0.77--1.96)   0.83           1.06 (0.62--1.82)
  AG                                                    CT   139 (21.7%)   378 (22.3%)                                         6.00×10^-3^                                                       1.70 (1.16--2.50)   0.02           1.68 (1.08--2.63)
  AG                                                    TT   96 (15.0%)    163 (9.6%)                                          1.43×10^-6^                                                       2.73 (1.80--4.13)   1.80×10^-4^    2.49 (1.54--4.10)
  AA                                                    CC   10 (1.6%)     47 (2.8%)                                           0.97                                                              1.02 (0.48--2.17)   0.85           1.09(0.47--2.53)
  AA                                                    CT   47 (7.3%)     104 (6.1%)                                          2.00×10^-3^                                                       2.09 (1.30--3.37)   5.00×10^-3^    2.18 (1.27--3.76)
  AA                                                    TT   46 (7.2%)     46 (2.7%)                                           2.65×10^-9^                                                       4.63 (2.74--7.82)   4.34×10^-6^    4.04 (2.23--7.32)
  Replication II population 810 cases /1,627 controls                                                                                                                                                                               
  GG                                                    CC   44 (5.4%)     176 (10.8%)                                         N.A                                                               1.00                N.A            1.00
  GG                                                    CT   161 (19.9%)   379 (23.3%)                                         6.00×10^-3^                                                       1.70 (1.16--2.48)   6.00×10^-3^    1.75 (1.18--2.60)
  GG                                                    TT   108 (13.3%)   197 (12.1%)                                         1.22×10^-4^                                                       2.19 (1.46--3.29)   2.25×10^-4^    2.19 (1.44--3.32)
  AG                                                    CC   56 (6.9%)     162 (10.0%)                                         0.16                                                              1.38 (0.88--2.17)   0.09           1.50 (0.95--2.39)
  AG                                                    CT   189 (23.3%)   404 (24.8%)                                         1.00×10^-3^                                                       1.87 (1.29--2.72)   1.00×10^-3^    1.96 (1.34--2.87)
  AG                                                    TT   124 (15.3%)   160 (9.8%)                                          2.29×10^-8^                                                       3.10 (2.07--4.65)   4.36×10^-8^    3.22 (2.12--4.90)
  AA                                                    CC   15 (1.9%)     30 (1.8%)                                           0.05                                                              2.00 (0.99--4.04)   0.16           1.71 (0.81--3.58)
  AA                                                    CT   57 (7.0%)     74 (4.5%)                                           2.53×10^-6^                                                       3.08 (1.91--4.97)   4.66×10^-6^    3.19 (1.94--5.25)
  AA                                                    TT   56 (6.9%)     45 (2.8%)                                           1.92×10^-10^                                                      4.98 (2.98--8.31)   1.58×10^-10^   5.70 (3.34--9.71)
  Combined population 2,020 cases /5,315 controls                                                                                                                                                                                   
  GG                                                    CC   131 (6.5%)    605 (11.4%)                                         N.A                                                               1.00                N.A            1.00
  GG                                                    CT   396 (19.6%)   1,267 (23.8%)                                       1.00×10^-3^                                                       1.44 (1.16--1.80)   3.00×10^-3^    1.45 (1.13--1.85)
  GG                                                    TT   278 (13.8%)   579 (10.9%)                                         2.58×10^-11^                                                      2.22 (1.75--2.81)   5.47×10^-9^    2.14 (1.66--2.76)
  AG                                                    CC   121 (6.0%)    534 (10.0%)                                         0.74                                                              1.05 (0.80--1.38)   0.74           1.05 (0.78--1.42)
  AG                                                    CT   445 (22.0%)   1,202 (22.6%)                                       1.19×10^-6^                                                       1.71 (1.38--2.13)   2.49×10^-5^    1.66 (1.31--2.11)
  AG                                                    TT   319 (15.8%)   566 (10.6%)                                         3.15×10^-16^                                                      2.60 (2.06--3.29)   8.15×10^-14^   2.66 (2.06--3.43)
  AA                                                    CC   38 (1.9%)     128 (2.4%)                                          0.13                                                              1.37 (0.91--2.06)   0.18           1.17 (0.93--1.46)
  AA                                                    CT   144 (7.1%)    293 (5.5%)                                          3.17×10^-9^                                                       2.27 (1.73--2.99)   1.56×10^-8^    2.39 (1.77--3.34)
  AA                                                    TT   148 (7.3%)    141 (2.7%)                                          2.96×10^-27^                                                      4.85 (3.60--6.53)   8.00×10^-24^   5.36 (3.87--7.43)

OR: odds ratio; CI: confidence interval

^a^nominal *P* value and OR computed using Chi-square tests with Pearson's 2×2 contingency tables.

^b^nominal *P* value and OR computed using multivariable logistic regression analysis including age and gender as covariates.

![Odds ratios (ORs) for each two-locus genotype for GWAS SNPs rs2106261 in the *ZFHX3* gene and rs2200733 close to the *PITX2c* gene involved in the pathogenesis of AF after adjustment for covariates.\
For two SNPs, there are a total of 9 genotypes. The wild type or non-risk GGCC genotype was used as the reference and ORs for other genotypes were estimated against the reference genotype using multivariable logistic regression analysis by including the age and gender as covariates. A. Analysis of ORs in the Discovery population. B. Analysis of ORs in the Replication I population. C. Analysis of ORs in the Replication II population. D. Analysis of ORs in the combined population with the Discovery, Replication I and Replication II cohorts. \**P*\<0.01.](pgen.1005393.g001){#pgen.1005393.g001}

The ORs among the different genotypes were compared for statistical significance using the Breslow-Day test ([S5 Table](#pgen.1005393.s006){ref-type="supplementary-material"}). In all three independent populations as well as the combined population, ORs for genotype [AATT]{.ul} (double risk homozygotes for both rs2106261 and rs2200733) were significantly higher than the ORs for each single-risk homozygotes (GG[TT]{.ul}, homozygous risk genotype for rs2106261; [AA]{.ul}CC, homozygous risk genotype for rs2200733) ([Table 1](#pgen.1005393.t001){ref-type="table"} and [S5 Table](#pgen.1005393.s006){ref-type="supplementary-material"}). Moreover, the OR of 6.64 for double-risk homozygote [AATT]{.ul} was higher than the combined ORs for the two single-risk homozygotes GG[TT]{.ul} and [AA]{.ul}CC together (2.14+1.25 = 3.39) in the Discovery population ([Table 1](#pgen.1005393.t001){ref-type="table"}, [Fig 1](#pgen.1005393.g001){ref-type="fig"} and [S1 Fig](#pgen.1005393.s001){ref-type="supplementary-material"}). Similar findings were observed in the Replication I population (4.34 vs. 3.25 (2.16+1.09)), the replication II population (5.70 vs. 3.90 (2.19+1.71)), or the combined cohort (5.36 vs. 3.31 (2.14+1.17)) ([Table 1](#pgen.1005393.t001){ref-type="table"}, [Fig 1](#pgen.1005393.g001){ref-type="fig"} and [S1 Fig](#pgen.1005393.s001){ref-type="supplementary-material"}). These data provide genetic evidence for interaction between *ZFHX3* variant rs2106261 and *PITX2c* variant rs2200733, which generates a synergistic effect that markedly increases the risk of AF.

Two other genotypes, GG[TT]{.ul} and AG[TT]{.ul}, significantly increased risk of AF compared to reference non-risk genotype GGCC, consistently in all three populations (*Padj*\<0.006 after Bonferroni correction) ([Table 1](#pgen.1005393.t001){ref-type="table"}, [Fig 1](#pgen.1005393.g001){ref-type="fig"} and [S1 Fig](#pgen.1005393.s001){ref-type="supplementary-material"}).

Molecular basis of gene-gene interaction: *PITX2c* positively regulates the expression of *ZFHX3* via miR-1 {#sec005}
-----------------------------------------------------------------------------------------------------------

To substantiate the novel finding of the genetic interaction between rs2106261 and rs2200733 as identified by the analyses above, we carried out functional studies to identify the underlying molecular mechanism of the interaction. The *PITX2c* gene near rs2200733 has been demonstrated to be an AF gene using mouse models and shown to regulate several genes in the atria \[[@pgen.1005393.ref013]--[@pgen.1005393.ref015]\]. Because *PITX2c* encodes a transcriptional factor, we hypothesized that *PITX2c* would regulate the expression of *ZFHX3*, generating a synergistic effect for gene-gene interaction. To test this hypothesis, we transfected HCT116 cells with a *PITX2c*-specific siRNA and a negative control siRNA (NC control) and then used real-time RT-PCR analysis to measure the expression level of *ZFHX3*. As shown in [Fig 2](#pgen.1005393.g002){ref-type="fig"}, knockdown of *PITX2c* expression by siRNA significantly decreased the expression level of *ZFHX3* (*P* = 4.00×10^-3^) ([Fig 2A and 2C](#pgen.1005393.g002){ref-type="fig"}). In a parallel study, overexpression of a FLAG-tagged PITX2c protein by transfection of a p3×FLAG-PITX2c expression plasmid significantly increased the expression level of *ZFHX3* (*P* = 0.01) ([Fig 2B and 2C](#pgen.1005393.g002){ref-type="fig"}). These studies indicate that *PITX2c* positively regulates expression of *ZFHX3*.

![The *PITX2c* gene positively regulates expression of the *ZFHX3* gene. HCT116 cells were transfected with siRNA specific for *PITX2c* or an expression plasmid for *PITX2c* and used for isolation of total RNA samples and real time RT-PCR analysis.\
A. Real-time RT-PCR analysis for *PITX2c*. Transfection of siRNA for *PITX2c* successfully reduced expression of *PITX2c*. B. Real-time RT-PCR analysis for *PITX2c*. Transfection of an expression plasmid for *PITX2c* successfully increased expression of *PITX2c*. C. Real-time RT-PCR analysis for *ZFHX3*. Transfection of siRNA for *PITX2c* reduced expression of *ZFHX3*. Transfection of an expression plasmid for *PITX2c* successfully increased expression of *ZFHX3*. \*\**P*\<0.01.](pgen.1005393.g002){#pgen.1005393.g002}

To explore the molecular mechanism by which *PITX2c* regulates *ZFHX3*, we searched for a potential *PITX2c* binding site at the *ZFHX3* promoter and regulatory region, but failed to find one. Because *PITX2c* was shown to negatively regulate the expression of *miR-1* (microRNA 1--1) \[[@pgen.1005393.ref015]\], we hypothesize that *PITX2c* may regulate expression of *ZFHX3* through *miR-1*. To test this hypothesis, we transfected HCT116 cells with *miR-1* mimics and control microRNA mimics and measured the expression level of *ZFHX3*. Both real-time RT-PCR analysis and Western blot analysis showed that *miR-1* mimics significantly decreased expression of *ZFHX3* at both mRNA (*P* = 4.00×10^-4^) and protein levels (*P* = 6.84×10^-5^), although the effect on the protein level was more robust ([Fig 3A--3C](#pgen.1005393.g003){ref-type="fig"}). This interesting finding of down-regulation of *ZFHX3* by *miR-1* was confirmed in another cell line, SW620 at the *ZFHX3* mRNA (*P* = 0.01) and protein levels (*P* = 4.89×10^-4^) ([Fig 3D--3F](#pgen.1005393.g003){ref-type="fig"}). These results suggest that *miR-1* negatively regulates expression of *ZFHX3*.

![Expression of *ZFHX3* is negatively regulated by *miR-1*.\
HCT116 (**A-C**) and SW620 (**D-F**) cells were transfected with miR-1 mimics and negative control mimics (NC) and used for isolation of RNA samples for real-time RT-PCR analysis or for isolation of protein extracts for Western blot analysis for the expression levels of *ZFHX3* mRNA and protein. A. Real-time RT-PCR analysis revealed that the *miR-1* mimics reduced the expression of *ZFHX3* by 20% in HCT116 cells (*P* = 0.004). B, C. Western blot analysis revealed that the *miR-1* mimics reduced the expression of the ZFHX3 protein by 54% in HCT116 cells (*P* = 6.84×10^-5^). D. Real-time RT-PCR analysis revealed that the *miR-1* mimics reduced the expression of *ZFHX3* by 27% in SW620 cells (*P* = 0.01). E, F. Western blot analysis revealed that the *miR-1* mimics reduced the expression of the ZFHX3 protein by 45% in SW620 cells (*P* = 4.887×10^-4^). G. Identification of two putative *miR-1* binding sites at the 3'-UTR of *ZFHX3* by bioinformatic analysis and alignment of miR-1 binding sequences across species. H. A schematic diagram shows luciferase reporters containing the potential miR-1 binding site or the related mutated site. I. *MiR-1* targets the second *miR-1* binding site to regulate expression of *ZFHX3*. Luciferase assays revealed that compared to negative control mimics, miR-1 mimics significantly reduced luciferase activities from pMIR-ZFHX3--3'-UTR-2, but not from pMIR-ZFHX3-3'-UTR-1. \**P*\<0.05; \*\**P*\<0.01.](pgen.1005393.g003){#pgen.1005393.g003}

To explore the molecular mechanism by which *miR-1* regulates *ZFHX3*, we performed bioinformatic analysis by searching two databases, DIANA TOOLs and microRNA.org-Target and Expression, and found that the 3'-untranslated region (3'-UTR) of *ZFHX3* contained two potential targeting sites for *miR-1* ([Fig 3G](#pgen.1005393.g003){ref-type="fig"}). We cloned each region containing a *miR-1* binding site downstream of the firefly luciferase coding region in the pMIR-REPORT luciferase vector, resulting in luciferase reporters pMIR-ZFHX3-3'-UTR-1 (cloned genomic region: chr16: 72819500 to 72820662) and pMIR-ZFHX3--3'-UTR-2 (cloned genomic region: chr16: 72818241 to 72819390), respectively ([Fig 3H](#pgen.1005393.g003){ref-type="fig"}). Each reporter was co-transfected with *miR-1* mimics (100 nM) into HCT116 cells and luciferase assays were carried out. A schematic diagram shows luciferase reporters containing the potential *miR-1* binding site or the related mutated site ([Fig 3H](#pgen.1005393.g003){ref-type="fig"}). As shown in [Fig 3I](#pgen.1005393.g003){ref-type="fig"}, *miR-1* mimics significantly reduced luciferase activities from pMIR-ZFHX3--3'-UTR-2, but not that from pMIR-ZFHX3--3'-UTR-1. Mutation of the miR-1 binding site in pMIR-ZFHX3--3'-UTR-2 from CATTCCA to TGCGAAC abolished the *miR-1*-mediated reduction of the reporter luciferase activity ([Fig 3I](#pgen.1005393.g003){ref-type="fig"}). These data suggest that *miR-1* negatively regulates expression of *ZFHX3* by targeting to the second binding site at the 3'-UTR of *ZFHX3*.

Molecular basis of gene-gene interaction: *ZFHX3* positively regulates the expression of *PITX2c* {#sec006}
-------------------------------------------------------------------------------------------------

The AF SNP rs2106261 identified by GWAS is located within the *ZFHX3* gene, therefore, we consider *ZFHX3* as a strong candidate gene for AF at the chromosome 16q22 locus. As our genetic studies indicate a gene-gene interaction between *PITX2c* and *ZFHX3*, we hypothesized that *ZFHX3* may regulate expression of *PITX2c*. Interestingly, knockdown of *ZFHX3* expression by a specific siRNA significantly decreased expression of *PITX2c* about 2-fold (*P* = 5.00×10^-3^) ([Fig 4A and 4C](#pgen.1005393.g004){ref-type="fig"}). Conversely, overexpression of *ZFHX3* significantly increased expression of *PITX2c* by 2.96-fold (*P* = 2.00×10^-3^) ([Fig 4B and 4D](#pgen.1005393.g004){ref-type="fig"}). Knockdown of *ZFHX3* expression by siRNA reduced the transactivation activity from a reporter with a 1.5 kb DNA fragment upstream of the *PITX2c* transcriptional start site fused to the luciferase gene (PITX2c-PGL3) by 1.97-fold (*P* = 5.00×10^-3^) ([Fig 4E](#pgen.1005393.g004){ref-type="fig"}).

![The *ZFHX3* gene positively regulates expression of the *PITX2c* gene.\
HCT116 cells were transfected with siRNA specific for *ZFHX3* or an expression plasmid for *ZFHX3* and used for isolation of total RNA samples, real time RT-PCR analysis and Luciferase assays. A. Real-time RT-PCR analysis for *ZFHX3*. Transfection of siRNA for *ZFHX3* successfully reduced expression of *ZFHX3*. B. Real-time RT-PCR analysis for *ZFHX3*. Transfection of an expression plasmid for *ZFHX3* successfully increased expression of *ZFHX3*. C. Real-time RT-PCR analysis for *PITX2c*. Transfection of siRNA for *ZFHX3* reduced expression of *PITX2c*. D. Real-time RT-PCR analysis for *PITX2c*. Transfection of an expression plasmid for *ZFHX3* successfully increased expression of *PITX2c*. E. Luciferase assays for the *PITX2c* promoter activity in cells transfected with a siRNA specific for *ZFHX3* or a control scramble siRNA. \**P*\<0.05; \*\**P*\<0.01.](pgen.1005393.g004){#pgen.1005393.g004}

Molecular basis of gene-gene interaction: Both *PITX2c* and *ZFHX3* positively regulate the expression of *NPPA* {#sec007}
----------------------------------------------------------------------------------------------------------------

Several earlier studies showed that *PITX2c* regulates the expression of the *NPPA* gene encoding ANF (a cardiac protein hormone), but conflicting results on either positive regulation or negative regulation were obtained in different studies \[[@pgen.1005393.ref013],[@pgen.1005393.ref015],[@pgen.1005393.ref016]\]. We tested the regulation of *NPPA* by *PITX2c* in HCT116 cells. As showed in [Fig 5A](#pgen.1005393.g005){ref-type="fig"}, knockdown of *PITX2c* expression using siRNA significantly reduced expression of *NPPA* by 60% (*P* = 3.20×10^-4^). Overexpression of *PITX2c* by transfection of HCT116 cells with p3×FLAG-PITX2c significantly increased *NPPA* expression by 2.42 fold (*P* = 0.01) ([Fig 5B](#pgen.1005393.g005){ref-type="fig"}).

![Both *PITX2c* and *ZFHX3* positively regulate expression of the *NPPA* transcription.\
HCT116 cells were co-transfected with an expression plasmid for either *PITX2c*, *ZFHX3* or both, or siRNA for either *PITX2c*, *ZFHX3* or both and used for measurements of RT-PCR. A. Knockdown of *PITX2c*, *ZFHX3* or both by siRNAs down-regulated *NPPA* expression. B. Overexpression of either *PITX2c* or *ZFHX3* up-regulated *NPPA* expression. Co-expression of both *PITX2c* and *ZFHX3* dramatically increased *NPPA* expression. \**P*\<0.05; \*\**P*\<0.01.](pgen.1005393.g005){#pgen.1005393.g005}

Interestingly, we found that *ZFHX3* also regulated *NPPA* expression. As shown in [Fig 5A](#pgen.1005393.g005){ref-type="fig"}, knockdown of *ZFHX3* expression by siRNA significantly decreased expression of *NPPA* (*P* = 4.00×10^-3^). Overexpression of *ZFHX3* up-regulated *NPPA* expression 2.36 fold (*P* = 0.03) ([Fig 5B](#pgen.1005393.g005){ref-type="fig"}).

Overexpression of both *PITX2c* and *ZFHX3* dramatically increased expression of *NPPA* (*P* = 0.031) ([Fig 5B](#pgen.1005393.g005){ref-type="fig"}). Knockdown of both *PITX2c* and *ZFHX3* also reduced expression of *NPPA* (*P* = 1.00×10^-3^) ([Fig 5A](#pgen.1005393.g005){ref-type="fig"}).

It was reported that *PITX2c* could also regulate expression of other downstream genes including *NKX2*.*5* (encoding NK2 transcription factor related, locus 5), *TBX5* (encoding T-box 5), *KCNQ1* (encoding potassium voltage-gated channel, KQT-like subfamily, member 1), and *SCN1B* (encoding sodium channel, voltage-gated, type I, beta subunit) \[[@pgen.1005393.ref013],[@pgen.1005393.ref015],[@pgen.1005393.ref017],[@pgen.1005393.ref018]\]. As shown in [Fig 6](#pgen.1005393.g006){ref-type="fig"}, knockdown of the *PITX2c* expression by siRNA significantly increased expression of *NKX2*.*5* by 3.10-fold, *TBX5* by 2.32-fold, *KCNQ1* by 1.55-fold, and *SCN1B* by 1.27-fold. Interestingly, knockdown of the *ZFHX3* gene by siRNA also significantly increased expression of *NKX2*.*5* by 3.45-fold and *TBX5* by 3.23-fold, but decreased expression of *SCN1B* by 1.52-fold and did not affect expression of *KCNQ1* ([Fig 6](#pgen.1005393.g006){ref-type="fig"}). Co-transfection of both *PITX2c* siRNA and *ZFHX3* siRNA also significantly reduced *NKX2*.*5* by 2.91-fold, *TBX5* by 2.42-fold, but did not affect expression of *KCNQ1* or *SCN1B* ([Fig 6](#pgen.1005393.g006){ref-type="fig"}).

![*PITX2c* and *ZFHX3* regulate expression of *NKX2*.*5*, *TBX5*, *KCNQ1* and *SCN1B*.\
HCT116 cells were transfected with siRNA specific for *PITX2c* or *ZFHX3* and used for isolation of total RNA samples and real-time RT-PCR analysis. Transfection of siRNA for *PITX2c* increased expression of *NKX2*.*5*, *TBX5*, *KCNQ1* and *SCN1B*. Transfection of siRNA for *ZFHX3* increased expression of *NKX2*.*5* and *TBX5*,but decreased expression of *SCN1B*. *ZFHX3* did not affect on the expression of *KCNQ1*. Transfection of siRNAs for both *PITX2c* and *ZFHX3* increased expression of *NKX2*.*5* and *TBX5*.](pgen.1005393.g006){#pgen.1005393.g006}

No significant gene-gene interaction between *ZFHX3* variant rs2106261 and *CAV1* variant rs3807989 or between *PITX2c* variant rs2200733 *CAV1* variant rs3807989 {#sec008}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

GWAS in European ancestry populations have identified ten genetic loci for AF \[[@pgen.1005393.ref005],[@pgen.1005393.ref007],[@pgen.1005393.ref008],[@pgen.1005393.ref010],[@pgen.1005393.ref011]\]. We analyzed these loci in the Chinese Han population for their association with AF. We found that in addition to the *ZFHX3* locus and the *PITX2c* locus reported previously \[[@pgen.1005393.ref006],[@pgen.1005393.ref009]\], one other locus, rs3807989 in *CAV1* encoding caveolin-1, also showed significant association with AF, whereas no significant association was identified for other loci \[[@pgen.1005393.ref012]\]. Therefore, we also analyzed gene-gene interactions between rs2106261 and rs3807989 and between rs2200733 and rs3807989. The classical gene-gene analysis by comparing ORs for the nine two-locus genotypes did not reveal any significant synergistic effect between rs2106261 and rs3807989 ([Table 2](#pgen.1005393.t002){ref-type="table"}). The OR for the double risk homozygotes for both rs2106261 and rs3807989 ([AAGG]{.ul}) was 1.25, which is smaller than the product of the ORs (1.18+1.15) for each single-risk homozygotes ([AA]{.ul}AA, homozygous risk genotype for rs2106261; GG[GG]{.ul}, homozygous risk genotype for rs3807989) ([Table 2](#pgen.1005393.t002){ref-type="table"}). These results suggest that there is no interaction between the *ZFHX3* locus and the *CAV1* locus for AF. Similarly, the OR for the double risk homozygotes for both rs2200733 and rs3807989 ([TTGG]{.ul}) was 1.08, which is smaller than the product of the ORs (1.00+0.77) for each single-risk homozygotes ([TT]{.ul}AA, homozygous risk genotype for rs2200733; CC[GG]{.ul}, homozygous risk genotype for rs3807989) ([Table 2](#pgen.1005393.t002){ref-type="table"}). These results suggest that there is no interaction between the *PITX2c* locus and the *CAV1* locus for AF.

10.1371/journal.pgen.1005393.t002

###### ORs for 8 two-locus genotypes versus non-risk homozygous genotype AAGG as a reference for SNPs rs2106261 and rs3807989, CCAA as a reference for SNPs rs2200733 and rs3807989 in the Chinese Han population.

![](pgen.1005393.t002){#pgen.1005393.t002g}

  Two-locus genotype                               Allelic test[^a^](#t002fn002){ref-type="table-fn"}   Adjust for age and gender[^b^](#t002fn003){ref-type="table-fn"}                                      
  ----------------------------- ---- ------------- ---------------------------------------------------- ----------------------------------------------------------------- -------------------- ------------- --------------------
  1,578 cases /2,389 controls                                                                                                                                                                                
  GG                            AA   44 (1.1%)     110 (4.6%)                                           N.A‡                                                              1.00                 N.A           1.00
  GG                            AG   221 (5.6%)    442 (18.5%)                                          0.255                                                             1.25 (0.85--1.84)    0.79          1.06 (0.69--1.63)
  GG                            GG   357 (22.6%)   577 (24.2%)                                          0.021                                                             1.55 (1.06--2.25)    0.19          1.15 (0.93--1.42)
  AG                            AA   47 (3.0%)     93 (3.9%)                                            0.354                                                             1.26 (0.77--2.78)    0.66          1.04 (0.87--1.25)
  AG                            AG   253 (16.0%)   383 (16.0%)                                          0.10                                                              1.64 (1.12--2.44)    0.02          1.27 (1.03--1.54)
  AG                            GG   403 (25.5%)   520 (21.8%)                                          4.34×10^-4^                                                       1.92 (1.33--2.78)    4.58×10^-4^   2.04 (1.37--3.03)
  AA                            AA   18 (1.1%)     14 (0.6%)                                            3.00×10^-3^                                                       3.23 (1.47--7.14)    0.02          1.18 (1.03--1.35)
  AA                            AG   78 (4.9%)     97 (4.1%)                                            0.003                                                             2.01 (1.27--3.23)    8.00×10^-3^   1.15 (1.03--1.27)
  AA                            GG   157 (9.9%)    153 (6.4%)                                           6.23×10^-6^                                                       2.57 (1.70--3.88)    6.62×10^-5^   1.25 (1.12--1.40)
  1,578 cases /2,389 controls                                                                                                                                                                                
  **rs2200733 rs3807989**                                                                                                                                                                                    
  CC                            AA   24 (1.5%)     43 (1.8%)                                            N.A                                                               1.00                 N.A           1.00
  CC                            AG   79 (5.0%)     234 (9.8%)                                           0.08                                                              0.61 (0.345--1.06)   0.03          0.50 (0.262--0.94)
  CC                            GG   121 (7.7%)    317 (13.3%)                                          0.17                                                              0.68 (0.40--1.18)    0.09          0.77 (0.568--1.04)
  CT                            AA   44 (6.9%)     111 (4.6%)                                           0.27                                                              0.71 (0.386--1.31)   0.15          0.85 (0.68--1.06)
  CT                            AG   271 (17.2%)   485 (20.3%)                                          1.00                                                              1.00 (0.60--1.69)    0.53          0.95 (0.83--1.10)
  CT                            GG   454 (28.8%)   650 (27.2%)                                          0.39                                                              1.25 (0.75--2.09)    0.82          0.99 (0.88--1.11)
  TT                            AA   41 (2.6%)     63 (2.6%)                                            0.64                                                              1.17 (0.62--2.20)    0.96          1.00 (0.88--1.12)
  TT                            AG   202 (12.8%)   203 (8.5%)                                           0.03                                                              1.78 (1.04--3.05)    0.30          1.05 (0.96--1.41)
  TT                            GG   342 (21.7%)   283 (11.8%)                                          3.00×10^-3^                                                       2.17 (1.28--3.66)    0.03          1.08 (1.01--1.16)

OR: odds ratio; CI: confidence interval

^a^nominal *P* value and OR computed using Chi-square tests with Pearson's 2×2 contingency tables.

^b^nominal *P* value and OR computed using multivariable logistic regression analysis including age and gender as covariates.

Real-time RT-PCR analysis showed that knockdown of either *ZFHX3* or *PITX2c* increased the expression level of *CAV1* ([Fig 7](#pgen.1005393.g007){ref-type="fig"}). Similar results were obtained with Western blot analysis ([Fig 7](#pgen.1005393.g007){ref-type="fig"}). On the contrary, knockdown of *CAV3* did not significantly affect the expression of *ZFHX3* or *PITX2c* ([Fig 8](#pgen.1005393.g008){ref-type="fig"}). Together, these data suggest that there is no cyclic cross-regulation between *ZFHX3* and *CAV1* or between *PITX2c* and *CAV1*.

![*PITX2c* and *ZFHX3* negatively regulate expression of the *CAV1* gene.\
HCT116 cells were transfected with siRNA specific for *PITX2c* or siRNA specific for *ZFHX3* and used for isolation of total RNA samples and real-time RT-PCR analysis. A. Real-time RT-PCR analysis for *CAV1*. Transfection of siRNA for *PITX2c* or siRNA for *ZFHX3* successfully increased expression of *CAV1*. B, C. Western blot analysis revealed that *PITX2c* and *ZFHX3* increased the expression of the CAV1 protein by 1.79-fold and 1.84-fold, respectively (*P* = 2.21×10^-5^, 2.00×10^-7^). \*\**P*\<0.01; \*\<0.05.](pgen.1005393.g007){#pgen.1005393.g007}

![The *CAV1* gene does not affect expression of *PITX2c* or *ZFHX3*.\
HCT116 cells were transfected with siRNA specific for *CAV1* and used for isolation of total RNA samples and real-time RT-PCR analysis. A. Real-time RT-PCR analysis for *PITX2*. Transfection of siRNA for *CAV1* did not significantly affect the expression of *PITX2*. B. Real-time RT-PCR analysis for *ZFHX3*. Transfection of siRNA for *CAV1* did not significantly affect the expression of *ZFHX3*. *C*. Real-time RT-PCR analysis for *CAV1*. Transfection of siRNA for *CAV1* successfully reduced expression of *CAV1*.\*\**P*\<0.01; \*\<0.05.](pgen.1005393.g008){#pgen.1005393.g008}

Analysis of gene-gene interactions by alternative gene-gene interaction programs {#sec009}
--------------------------------------------------------------------------------

Many gene-gene programs have been developed in recent years, therefore, we also analyzed interaction among SNPs rs2200733/*PITX2c*, rs2106261/*ZFHX3* and rs3807989/*CAV1* using RERI and INTERSNP programs. RERI (relative excess risk due to interaction) analysis was developed to quantify the extent of synergistic effect by adopting a fundamental measure of additive interaction and relative excess risk due to interaction (RERI) \[[@pgen.1005393.ref019]\]. Here we used this strategy to investigate interaction between rs2106261 and rs2200733 in terms of risk alleles A and T in the combined population. The RERI analysis can distinguish the additive effect from the synergistic effect \[[@pgen.1005393.ref019]\]. A significant RERI value higher or lower than 0 is considered to demonstrate a synergistic effect, whereas a non-significant RERI value indicates an additive effect \[[@pgen.1005393.ref019]\]. The results are shown in [Table 3](#pgen.1005393.t003){ref-type="table"}. First, we analyzed the synergistic effect when exposed to one copy of risk alleles at any one locus or both loci (H1). No significant synergistic effect was observed between rs2106261 and rs2200733 (RERI = 0.22 (95% CI -0.20--0.54), *P* = 0.13; RERI = 0.18 (95% CI -0.29--0.52), *Padj* = 0.22 after adjustment of covariates of age and gender). Second, we assessed the synergistic effect when exposed to two copies of risk alleles at any one locus or both loci (H2). A significant synergistic effect was detected between rs2106261 and rs2200733 with a RERI value of 2.26 (95% CI 1.06--3.73) (*P\<1*.*00*×10^-4^; RERI = 2.87 (1.48--4.69), *Padj\<1*.*00*×10^-4^ after adjustment of covariates of age and gender). Third, we assessed the synergistic effect when exposed to two copies of risk alleles at one locus and one copy of risk alleles at the other locus (H3). A significant synergistic effect was detected between rs2106261 and rs2200733 with a RERI value of 0.99 (95% CI 0.29--1.79) (*P\<1*.*00*×10^-4^; RERI = 1.29 (95% CI 0.44--2.33), *Padj\<1*.*00*×10^-4^ after adjustment of covariates of age and gender). These results provided statistical genetic evidence for the interaction between rs2106261 and rs2200733.

10.1371/journal.pgen.1005393.t003

###### Interaction between SNPs rs2106261 and rs2200733 in the Chinese Han population.

![](pgen.1005393.t003){#pgen.1005393.t003g}

  Exposed   Genotype                      N of case   N of control   RERI (95%CI)   *P* [^b^](#t003fn003){ref-type="table-fn"}   RERI~adj~ (95%CI) [^a^](#t003fn002){ref-type="table-fn"}   *P* [^b^](#t003fn003){ref-type="table-fn"}   
  --------- ----------------------------- ----------- -------------- -------------- -------------------------------------------- ---------------------------------------------------------- -------------------------------------------- ---------------
            2,020 cases /5,315 controls                                                                                                                                                                                                  
  H1        AG                            CT          445            1202           0.22 (-0.20--0.54)                           0.13                                                       0.18(-0.29--0.52)                            0.22
            GG                            CT          396            1267                                                                                                                                                                
            AG                            CC          121            534                                                                                                                                                                 
            GG                            CC          131            605                                                                                                                                                                 
  H2        AA                            TT          148            141            2.26 (1.06--3.73)                            \<1.00×10^-4^                                              2.87(1.48--4.69)                             \<1.00×10^-4^
            GG                            TT          278            579                                                                                                                                                                 
            AA                            CC          38             128                                                                                                                                                                 
            GG                            CC          131            605                                                                                                                                                                 
  H3        AA                            TT          148            141            0.99 (0.29--1.79)                            \<1.00×10^-4^                                              1.29(0.44--2.33)                             \<1.00×10^-4^
            AG                            TT          319            566                                                                                                                                                                 
            AA                            CT          144            293                                                                                                                                                                 
            AG                            CT          445            1202                                                                                                                                                                

H1: Exposed to one copy of risk alleles; H2: Exposed to two copies of risk allele; H3: Exposed to one additional copy of risk allele

^a^RERI~adj~ were computed by adjusting for age and gender.

^b^ *P* values were estimated by 10000 times of bootstrap sampling.

The RERI analysis did not identify any significant interaction between *ZFHX3* SNP rs2106261 and *CAV1* variant rs3807989 (H1: RERI = 0.51 (95% CI -0.54--1.12), *Padj* = 0.19; H2: RERI = -0.52 (95% CI -5.64--1.41), *Padj* = 0.37; H3: RERI = 0.29 (95% CI -0.61--1.06), *Padj* = 0.36) ([Table 4](#pgen.1005393.t004){ref-type="table"}). The RERI analysis was also used to analyze the interaction between *PITX2c* variant rs2200733 and *CAV1* variant rs3807989 (H1: RERI = 0.80 (95% CI -0.02--1.27), *Padj* = 0.11; H2: RERI = 1.37 (95% CI 0.24--2.71), *Padj* = 0.05; H3: RERI = 0.42 (95% CI -0.33--1.12), *Padj* = 0.08).

10.1371/journal.pgen.1005393.t004

###### Interaction analysis of rs2106261 vs. rs3807898 and rs2200733 vs. rs3807898 in the Chinese Han population.

![](pgen.1005393.t004){#pgen.1005393.t004g}

  Exposed   Genotype                      N of case       N of control   RERI (95%CI)   *P* [^b^](#t004fn003){ref-type="table-fn"}   RERI~adj~ (95%CI) [^a^](#t004fn002){ref-type="table-fn"}   *P* [^b^](#t004fn003){ref-type="table-fn"}   
  --------- ----------------------------- --------------- -------------- -------------- -------------------------------------------- ---------------------------------------------------------- -------------------------------------------- ------
            **rs2106261**                 **rs3807989**                                                                                                                                                                                      
            1,578 cases /2,389 controls                                                                                                                                                                                                      
  H1        AG                            AG              253            383            0.14 (-1.07--0.75)                           0.71                                                       0.51 (-0.54--1.12)                           0.19
            GG                            AG              221            442                                                                                                                                                                 
            AG                            AA              47             93                                                                                                                                                                  
            GG                            AA              44             110                                                                                                                                                                 
  H2        AA                            GG              157            153            -1.20 (-6.36--0.80)                          0.09                                                       -0.52 (-5.64--1.41)                          0.37
            GG                            GG              357            577                                                                                                                                                                 
            AA                            AA              18             14                                                                                                                                                                  
            GG                            AA              44             110                                                                                                                                                                 
  H3        AA                            GG              157            153            0.16 (-0.59--0.81)                           0.60                                                       0.29(-0.61--1.06)                            0.36
            AG                            GG              403            520                                                                                                                                                                 
            AA                            AG              78             97                                                                                                                                                                  
            AG                            AG              253            383                                                                                                                                                                 
            **rs2200733**                 **rs3807989**                                                                                                                                                                                      
            1,578 cases /2,389 controls                                                                                                                                                                                                      
  H1        CT                            AG              271            485            0.69 (-0.22--1.14)                           0.15                                                       0.80(-0.02--1.27)                            0.11
            CC                            AG              79             234                                                                                                                                                                 
            CT                            AA              44             111                                                                                                                                                                 
            CC                            AA              24             43                                                                                                                                                                  
  H2        TT                            GG              342            283            1.32 (0.15--2.58)                            0.04                                                       1.37(0.24--2.71)                             0.05
            CC                            GG              121            317                                                                                                                                                                 
            TT                            AA              41             63                                                                                                                                                                  
            CC                            AA              24             43                                                                                                                                                                  
  H3        TT                            GG              342            283            0.13 (-0.58--0.76)                           0.56                                                       0.42 (-0.33--1.12)                           0.08
            CT                            GG              319            566                                                                                                                                                                 
            TT                            AG              454            650                                                                                                                                                                 
            CT                            AG              271            485                                                                                                                                                                 

H1: Exposed to one copy of risk alleles; H2: Exposed to two copies of risk allele; H3: Exposed to one additional copy of risk allele

^a^RERI~adj~ were computed by adjusting for age and gender.

^b^ *P* values were estimated by 10000 times of bootstrap sampling.

We also analyzed gene-gene interaction using the INTERSNP program\[[@pgen.1005393.ref020],[@pgen.1005393.ref021]\], which can analyze genotypic interactions under additive by additive, additive by dominant, dominant by additive and dominant by dominant terms. For rs2106261 and rs2200733, nominal significant interaction was found additive × additive after adjusting for age and gender (OR = 0.85, 95% CI: 0.74--0.97, *Padj* = 0.02), although the global test on all interaction terms were not significant ([Table 5](#pgen.1005393.t005){ref-type="table"}). After simplifying the model by removing dominant effects without significant loss of goodness-of-fit of the model (*P* = 0.11), the additive interaction on a multiplicative OR scale was also significant (OR = 0.85, 95% CI: 0.76--0.96, *Padj* = 0.01) ([Table 5](#pgen.1005393.t005){ref-type="table"}). A similar pattern was found for additive × additive interaction between rs2200733 and rs3807989 under models with dominant effects (OR = 1.40, 95% CI: 1.16--1.70, *Padj* = 1.00×10^-3^) and after removing dominant effects (OR = 1.25, 95% CI: 1.06--1.48, *Padj* = 7.00×10^-3^). No significant genotypic interaction was found for rs2106261 and rs3807989 under any model ([Table 5](#pgen.1005393.t005){ref-type="table"}).

10.1371/journal.pgen.1005393.t005

###### Genotypic interaction with logistic regression by INTERSNP developed by Cordell and Clayton \[[@pgen.1005393.ref020],[@pgen.1005393.ref021]\].

![](pgen.1005393.t005){#pgen.1005393.t005g}

  ------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------
  **SNP Pair: rs2106261 by rs2200733**                                                                                                                                                                                                   
  **Genotypic interaction (test \#6)**        **OR (95%CI)** [^**a**^](#t005fn002){ref-type="table-fn"}   ***P*** [^**a**^](#t005fn002){ref-type="table-fn"}   **OR** ~**adj**~ **(95%CI)** [^**b**^](#t005fn003){ref-type="table-fn"}   ***P*** ~***adj***~ [^**b**^](#t005fn003){ref-type="table-fn"}
  A×A                                         0.89 (0.79--1.01)                                           0.06                                                 0.85 (0.74--0.97)                                                         0.02
  A×D                                         0.95 (0.81--1.13)                                           0.57                                                 0.95 (0.79--1.14)                                                         0.55
  D×A                                         1.06 (0.89--1.26)                                           0.50                                                 1.09 (0.90--1.31)                                                         0.39
  D×D                                         1.12 (0.89--1.42)                                           0.34                                                 1.07 (0.83--1.38)                                                         0.60
                                                                                                          Global *P* = 0.23                                                                                                              Global *P* = 0.11
  **Additive interaction model (test \#5)**                                                                                                                                                                                              
  A×A                                         0.89 (0.80--1.00)                                           0.04                                                 0.85 (0.76--0.96)                                                         0.01
  **SNP Pair: rs2106261 by rs3807989**                                                                                                                                                                                                   
  **Genotypic interaction (test \#6)**        **OR (95%CI)**                                              ***P***                                              **OR** ~**adj**~ **(95%CI)**                                              ***P*** ~***adj***~
  A×A                                         1.18 (0.96--1.45)                                           0.12                                                 1.09(0.87--1.37)                                                          0.47
  A×D                                         0.84(0.64--1.09)                                            0.18                                                 0.88(0.65--1.19)                                                          0.41
  D×A                                         0.85(0.65--1.13)                                            0.25                                                 0.78(0.57--1.06)                                                          0.11
  D×D                                         1.26(0.88--1.81)                                            0.22                                                 1.46(0.97--2.19)                                                          0.07
                                                                                                          Global *P* = 0.52                                                                                                              Global *P* = 0.44
  **Additive interaction model (test \#5)**                                                                                                                                                                                              
  A×A                                         1.06 (0.92--1.23)                                           0.43                                                 0.99 (0.84--1.17)                                                         0.95
  **SNP Pair: rs2200733 by rs3807989**                                                                                                                                                                                                   
  **Genotypic interaction (test \#6)**        **OR (95%CI)**                                              ***P***                                              **OR** ~**adj**~ **(95%CI)**                                              ***P*** ~***adj***~
  A×A                                         1.28(1.08--1.52)                                            4.41×10^-3^                                          1.40(1.16--1.70)                                                          1.00×10^-3^
  A×D                                         0.81(0.64--1.02)                                            0.07                                                 0.79(0.61--1.03)                                                          0.08
  D×A                                         0.80(0.62--1.03)                                            0.08                                                 0.76(0.57--1.00)                                                          0.05
  D×D                                         1.17(0.84--1.64)                                            0.35                                                 1.37(0.95--1.99)                                                          0.09
                                                                                                          Global *P* = 0.05                                                                                                              Global *P* = 9.00×10^-3^
  **Additive interaction model (test \#5)**                                                                                                                                                                                              
  A×A                                         1.16 (1.00--1.34)                                           0.06                                                 1.25 (1.06--1.48)                                                         7.00×10^-3^
  ------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------

A: Additive; D: Dominant; OR: odds ratio; 95% CI: 95% confidence interval.

^a^OR and 95% CI before adjustment for age and gender.

^b^OR and 95% CI after adjustment for age and gender.

Discussion {#sec010}
==========

In this study, we show that gene-gene interaction plays an important role in generation of disease phenotype by identifying gene-gene interaction involved in the pathogenesis of a cardiac disorder, AF. We employed a multi-stage case control association design to compare the frequencies of all nine two-locus genotypes from GWAS SNPs rs2106261 in the *ZFHX3* gene and rs2200733 close to the *PITX2c* gene. Our study involves a careful design with a Discovery population consisting of 569 cases and 1,996 controls, Replication I population with 641 cases and 1,692 controls, and Replication II population composed of 810 cases and 1,627 controls. The combined population has 2,020 cases and 5,315 controls, and is considered to represent a considerably large sample size in the modern population studies for AF. We consider this point as strength of this study. When SNP rs2106261 and rs2200733 were analyzed together, two-locus genotype AATT (double risk homozygote) showed the highest odds ratio (OR) of 6.64 (95% CI 3.64--12.11) (*P* = 6.38×10^-10^), 4.04 (95% CI 2.23--7.32) (*P* = 4.34×10^-6^), 5.70 (95% CI 3.34--9.71) (*P* = 1.58×10^-10^) and 5.36 (95% CI 3.87--7.43) (*P* = 8.00×10^-24^) in the Discovery, Replication I, II, and combined population, respectively, when compared to wild type non-risk genotype GGCC. The Breslow-Day test showed that the ORs for [AATT]{.ul} were significantly higher than ORs for GG[TT]{.ul} or [AA]{.ul}CC in all populations (*P* = 5.26×10^-5^ vs. GG[TT]{.ul} and 2.94×10^-22^ vs. [AA]{.ul}CC in the combined population) and higher than the combined ORs for both GG[TT]{.ul} and [AA]{.ul}CC (5.36 vs. 3.31 in the combined population). We also analyzed gene-gene interaction using the RERI analysis and identified synergistic effects between SNP rs2106261 and rs2200733 when exposed two copies of risk alleles at any one locus or both loci (H2) (*P\<1*.*00*×10^-4^) or when exposed to two copies of risk alleles at one locus and one copy of risk alleles at the other locus (H3) (*P\<1*.*00*×10^-4^) ([Table 3](#pgen.1005393.t003){ref-type="table"}). Analysis using the INTERSNP program revealed significant genotypic interaction between SNP rs2106261 and rs2200733 under an additive × additive model, but not under other models ([Table 5](#pgen.1005393.t005){ref-type="table"}). Overall, our studies establish that gene-gene interaction is involved in the pathogenesis of AF. Most importantly, our results suggest that gene-gene interaction accounts for heritability of human disease because it generates synergistic effects that markedly increase disease risk.

The present study identifies the interaction between two common GWAS loci for AF. Ritchie et al \[[@pgen.1005393.ref022]\] previously found that the risk alleles of common variants rs2200733 and rs10033464 at the 4q25 *PITX2c* AF locus could predict whether carriers of rare mutations in *SCN5A* (encoding the cardiac sodium channel), *NPPA*, *KCNA5* (encoding potassium voltage-gated channel, shaker-related subfamily, member 5), and *NKX2*.*5* (encoding transcriptional factor NK2 homeobox 5) developed AF, suggesting potential interaction between common variants and rare mutation in familial AF. Moreover, Lubitz et al \[[@pgen.1005393.ref023]\] studied AF risk signals within nine GWAS loci and found that there are at least four distinct AF susceptibility signals at the 4q25 AF locus upstream of *PITX2c* that may increase the risk of AF by 5-fold together.

Our cellular and molecular biological studies here on rs2200733/*PITX2c* and rs2106261/*ZFHX3* identify a fundamental molecular mechanism underlying gene-gene interaction. SNP rs2200733 on 4q25 was the first genomic variant for AF identified by GWAS \[[@pgen.1005393.ref005]\] and located 146 kb from the *PITX2c* gene encoding a paired-like homeodomain transcription factor 2 involved in the asymmetrical development of the heart and other organs \[[@pgen.1005393.ref024]--[@pgen.1005393.ref026]\]. Heterozygous knockout *PITX2c* mice developed atrial arrhythmias (atrial flutter, atrial tachycardia) upon programmed stimulation \[[@pgen.1005393.ref013]\]. Kirchhof et al \[[@pgen.1005393.ref014]\] showed that *PITX2c* is expressed in human and mouse left atria. Isolated hearts from heterozygous *PITX2c* knockout mice developed AF upon programmed stimulation and showed shortened action potential duration \[[@pgen.1005393.ref014]\]. Chinchilla et al \[[@pgen.1005393.ref015]\] showed that the expression level of *PITX2c* was decreased in AF patients and that atria-specific, but not ventricle-specific knockout of *PITX2c*, resulted in differences in action potential amplitude and increased expression of *miR-1*. Therefore, all evidence to date strongly suggests that *PITX2c* should be the causative gene for AF at the 4q25 locus. SNP rs2106261 is located within the *ZFHX3* gene. *ZFHX3* encodes a transcription factor \[[@pgen.1005393.ref027]\] which contains four homeodomains and seventeen zinc fingers \[[@pgen.1005393.ref028]\]. The ZFHX3 transcription factor appears to regulate myogenic \[[@pgen.1005393.ref029]\] and neuronal differentiation \[[@pgen.1005393.ref030]\]. Although the function of *ZFHX3* in cardiac tissue is unknown, it is expressed in mouse hearts \[[@pgen.1005393.ref031]\]. Here we show that *PITX2c* and *ZFHX3* positively cross-regulates each other. *PITX2c* negatively regulates expression of *miR-1*, which negatively regulates expression of *ZFHX3* by targeting a *miR-1*-binding site at the 3'-UTR, resulting in a positive regulation of *ZFHX3* by *PITX2c* ([Fig 9](#pgen.1005393.g009){ref-type="fig"}). Interestingly, *ZFHX3* positively regulates expression of *PITX2c*. The net effect is a cyclic loop of cross-regulation between *ZFHX3* and *PITX2c* ([Fig 9](#pgen.1005393.g009){ref-type="fig"}). A cyclic loop of cross-regulation of two risk genes for a disease is expected to generate synergistic effects, which further increase disease risk, and therefore provides a novel molecular mechanism for gene-gene interaction. One important future direction is to determine whether this novel mechanism applies to other human disease and to plant and animal phenotypes in general.

![A schematic diagram showing the cyclic cross-regulation of *PITX2c* and *ZFHX3*, which underlies the interaction between *PITX2c* and *ZFHX3* involved in the pathogenesis of AF.](pgen.1005393.g009){#pgen.1005393.g009}

On the molecular level, how does the cyclic loop of cross-regulation between *ZFHX3* and *PITX2c* generate interaction between the two genes and increase risk of AF? The expression level of *miR-1* was shown to be reduced in human AF patients, which was correlated with up-regulation of potassium channel Kir2.1 and increased potassium current I~K1~ responsible for AF maintenance. *PITX2c* negatively regulates expression of *miR-1*, which increases I~K1~, resulting in AF. Decreased *miR-1* increases expression of *ZFHX3*, which increases expression of *PITX2c*, further decreases expression of *miR-1* and increases risk of AF ([Fig 9](#pgen.1005393.g009){ref-type="fig"}). *ZFHX3* increases expression of *PITX2c*, which decreases expression of *miR-1* and increases risk of AF ([Fig 9](#pgen.1005393.g009){ref-type="fig"}). *PITX2c* positively regulates expression of *ZFHX3*, which further increases expression of *PITX2c*, and leads to down-regulation of *miR-1* expression and increased risk of AF ([Fig 9](#pgen.1005393.g009){ref-type="fig"}). In addition to *miR-1*, *PITX2c* and *ZFHX3* may regulate *NPPA*, *TBX5*, *NKX2*.*5* or other downstream target genes to increase risk of AF ([Fig 9](#pgen.1005393.g009){ref-type="fig"}). These results provide novel insights into the roles of gene-gene interaction in the pathogenesis of AF.

One other important insight from this study is that not all risk genes for AF interact each other. We have previously shown that genomic variants increase susceptibility of cardiovascular diseases in a population-specific manner. Although some variants increase disease risk in both European ancestry populations and Asian populations, but other variants show significant disease association only in Asian populations \[[@pgen.1005393.ref009],[@pgen.1005393.ref011],[@pgen.1005393.ref032]\]. For AF, we found that among ten GWAS variants for AF identified in European ancestry populations, only three were associated with risk of AF in the Chinese population, including SNPs rs2106261 in the *ZFHX3* gene, rs2200733 at the *PITX2c* locus, and rs3807989 in the *CAV1* gene. Despite the robust gene-gene interaction identified for rs2106261/*ZFHX3* gene and rs2200733/*PITX2c*, we did not identify any significant interaction between rs2106261/*ZFHX3* and rs3807989/*CAV1* with all three gene-gene interaction programs (Tables [2](#pgen.1005393.t002){ref-type="table"}, [4](#pgen.1005393.t004){ref-type="table"} and [5](#pgen.1005393.t005){ref-type="table"}). For interaction between rs2200733/*PITX2c* and rs3807989/*CAV1*, inconsistent results were obtained. Analysis for the OR for each multi-locus genotype and RERI analysis did not find gene-gene interaction between rs2200733 and rs3807989, whereas the INTERSNP program found significant interaction under a model of additive by additive. Future studies are needed to reconcile the differences between different programs developed for studying gene-gene interaction.

One limitation of the present study is that our statistical analysis was not adjusted for principal components to correct for possible stratification in Chinese samples due to a limited number of SNPs genotyped in the study populations. Genetic interaction may be especially susceptible to small degrees of population stratification, however, this may be unlikely given the replication of the finding in multiple populations.

In summary, we have found that gene-gene interaction can generate synergistic effects that markedly increase disease risk, therefore, accounting for a portion of heritability of human disease. Our identification of the gene-gene interaction between SNPs rs2106261 in the *ZFHX3* gene and rs2200733 at the *PITX2c* locus provide significant insights into the pathogenesis of AF. We further show that *PITX2c* and *ZFHX3* positively regulate each other at the molecular level, generating a loop of cross-regulation between *PITX2c* and *ZFHX3*. Our data provide an interesting molecular basis for some gene-gene interaction at the molecular genetic level.

Materials and Methods {#sec011}
=====================

Study subjects and preparation of genomic DNA samples {#sec012}
-----------------------------------------------------

The subjects involved in the present study include AF patients and non-AF controls selected from the GeneID database \[[@pgen.1005393.ref006],[@pgen.1005393.ref009],[@pgen.1005393.ref032]--[@pgen.1005393.ref039]\]. All study subjects are of Han ethnic origin based on self-description. The study was approved by the Ethics Committee of Huazhong University of Science and Technology and the Ethics Committees from local hospitals, and consistent with the guideline in the Declaration of Helsinki. Written informed consent was obtained from the participants.

The diagnosis of AF was made by multiple experienced cardiologists and cardiac electrophysiologists using data from 12-lead surface electrocardiograms (ECGs) or Holter recordings. The ECG characteristics of AF include the absence of P waves, the presence of rapid oscillations or fibrillatory waves (F waves), and irregular R-R intervals \[[@pgen.1005393.ref040]--[@pgen.1005393.ref042]\]. The controls are healthy individuals who do not have AF at the time of physical examinations or from medical records.

Details of study subjects and GeneID and preparation of genomic DNA samples were described in [S1 Text](#pgen.1005393.s015){ref-type="supplementary-material"}.

Genotyping of SNPs {#sec013}
------------------

Genotyping of SNPs was carried out using High-Resolution Melt (HRM) analysis as described previously by us \[[@pgen.1005393.ref006],[@pgen.1005393.ref009],[@pgen.1005393.ref032]--[@pgen.1005393.ref039]\]. HRM genotyping data were validated by direct sequencing analysis of 52 randomly selected study subjects. Primers for genotyping are listed in [S6 Table](#pgen.1005393.s007){ref-type="supplementary-material"}. The HRM genotyping data matched the sequencing data.

Prediction of potential miR-1 binding sites {#sec014}
-------------------------------------------

Details of bioinformatics prediction of miR-1 binding sites were described in [S1 Text](#pgen.1005393.s015){ref-type="supplementary-material"}.

Plasmids, siRNAs, and microRNA mimics {#sec015}
-------------------------------------

Details of plasmids, siRNAs and microRNA mimics were described in [S1 Text](#pgen.1005393.s015){ref-type="supplementary-material"}.

Cell culture and dual luciferase reporter assays {#sec016}
------------------------------------------------

HCT116 and SW620 cells were cultured and transfected with plasmid DNA, siRNAs, and microRNA mimics using Lipofectamine 2000 and the Opti-MEM I reduced serum medium as described \[[@pgen.1005393.ref043],[@pgen.1005393.ref044]\]. Luciferase activities were measured using the Dual-Glo luciferase assay kit (Gibco Life Technologies, Gaithersburg, MD, USA) as described previously by us \[[@pgen.1005393.ref043],[@pgen.1005393.ref045]\]. Each experiment was performed in triplicate and repeated at least three times. Details of cell culture and luciferase assays were described in [S1 Text](#pgen.1005393.s015){ref-type="supplementary-material"}.

Real-time PCR analysis {#sec017}
----------------------

The expression levels of *PITX2c*, *ZFHX3*, *NPPA*, *CAV1*, *NKX2*.*5*, *TBX5*, *KCNQ1*, and *SCN1B* were measured using real-time RT-PCR analysis with SYBR green I mix as described by us previously \[[@pgen.1005393.ref036],[@pgen.1005393.ref044]\] and described in detail in [S1 Text](#pgen.1005393.s015){ref-type="supplementary-material"}. Primers for real-time RT- PCR analysis are listed in [S6 Table](#pgen.1005393.s007){ref-type="supplementary-material"}.

Western blot analysis {#sec018}
---------------------

Western blot analysis was carried out as described by us previously \[[@pgen.1005393.ref043],[@pgen.1005393.ref044]\] and described in detail in [S1 Text](#pgen.1005393.s015){ref-type="supplementary-material"}.

Statistical analysis {#sec019}
--------------------

The genotyping data for all SNPs are included in [S8](#pgen.1005393.s009){ref-type="supplementary-material"}--[S13](#pgen.1005393.s014){ref-type="supplementary-material"} Tables. The genotyping data from the control group for each SNP were first tested for the Hardy-Weinberg equilibrium using PLINK1.06 (<http://pngu.mgh.harvard.edu>). If a *P* value was \>0.01, the genotyping data were considered to be in the Hardy-Weinberg equilibrium. Genotypic frequencies in controls were all in Hardy-Weinberg equilibrium (*P*\>0.01). For case-control association analysis, we used Pearson's 2×2 and 2×3 contingency table χ^2^ tests as implemented in PLINK1.06 (<http://pngu.mgh.harvard.edu>) to compute the *P* values for allelic and genotypic associations, respectively. The same PLINK1.06 program was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for each association. In order to exclude confounding factors, multivariable logistic regression analysis was performed using SPSS 17.0 to adjust for gender and age.

For analysis of gene-gene interaction, SNP rs2106261 in *ZFHX3* or SNP rs2200733 at the *PITX2c* locus each has two alleles (G vs. A for rs2106261; C vs. T for rs2200733). The two SNPs together generate nine different genotypes. We defined the homozygous, non-risk (or protective) two-locus genotype GGCC as the reference group, and then estimated the OR of AF for each of the other eight two-locus genotypes GGCT, GGTT, AGCC, AGCT, AGTT, AACC, AACT, and AATT in relation to the reference genotype. The Pearson's 2×2 contingency table χ^2^ test was used to compute the nominal *P* values, ORs, and 95% CIs for each genotypic association using PLINK1.06. The Breslow-Day test was carried out to test whether the ORs between two different genotypes showed a statistically significant difference.

Gene-gene interaction was also measured by a relative excess risk due to interaction (RERI) analysis \[[@pgen.1005393.ref019]\]. The RERI analysis analyzes was suggested to be more meaningful for disease prevention and intervention in public health \[[@pgen.1005393.ref046]\], and advocated to be more biologically interpretable compared to that measured on the multiplicative scale \[[@pgen.1005393.ref047]\]. A synergistic effect was defined as the extent of the combined effect of the exposures in excess of the sum of their individual effects \[[@pgen.1005393.ref048]\]. We adopted a fundamental measure of RERI versus additive interaction to quantify the extent of synergistic effect in this study. The original form of RERI was defined as RERI = *RR* ~11~-*RR* ~10~-*RR* ~01~+1, where subscript 11, 10 and 01 denote relative risks (RR) for doubly-exposed and individually-exposed to each risk factor when treating doubly-unexposed as a reference. When a RERI value equals to 0, it indicates a perfect additive model. Any significant deviation from 0 indicates a synergistic (+, positive values) or antagonistic (-, negative values) interaction. In a case-control study, RERI can be calculated by substituting ORs for RRs, yielding RERI = *OR* ~11~-*OR* ~10~-*OR* ~01~+1. Although simply replacing RRs with ORs would induce an exaggeration problem for ORs \[[@pgen.1005393.ref019],[@pgen.1005393.ref049]\], especially for a high prevalent disease, it is shown that RERI in terms of ORs is a good approximation of RERI in terms of RRs in a disease such as AF with a prevalence rate of 0.4%\~0.8%) \[[@pgen.1005393.ref049]\]. Under this circumstance, an OR is a good approximation of the RR. The statistical significance of RERI values in terms of ORs was addressed by the 95% confidence intervals based on the "MOVER" method, which utilizes the asymmetric intervals for ORs \[[@pgen.1005393.ref019]\]. Since the SNPs are bi-allelic, it is of interest to explore if the interaction exists (1) when doubly-exposed to one copy of risk alleles (i.e. doubly heterozygous genotype) and (2) when doubly-exposed to two copies of risk alleles (i.e. double homozygous risk genotypes). In both scenarios, the doubly-unexposed is referred to as the homozygous non-risk genotype (e.g. GGCC). In addition, we tested the interaction when exposed one additional copy of risk alleles given being exposed to one copy of risk alleles. Note that the doubly-unexposed in this scenario is the doubly heterozygous genotype (e.g. AGCT). The *P* values were estimated by 10,000 times of bootstrap sampling. The *P* value of 0.05 or less than and the 95% CI of RERI through zero was considered to show statistical significance.

We also conducted a 4 degree of freedom test for genotypic interaction with logistic regression developed by Cordell and Clayton\[[@pgen.1005393.ref020]\], which was implemented in the software INTERSNP\[[@pgen.1005393.ref021]\] as Logistic Regression test \#6. This model partitions the variance in AF risk into Additive and Dominant terms for each main effect, then into Additive by Additive, Additive by Dominant, Dominant by Additive and Dominant by Dominant terms. The test yielded ORs and 95% CI for each interaction term along with the global *P* values for the four terms. *P* values for individual terms were computed using Wald tests. We also used Logistic Regression test \#5 in the INTERSNP program to test for additive interaction on a multiplicative ORs scale.

In molecular studies with quantitative data, a standard Student's t-test was used to compare the means between two groups of variables. A *P* value of 0.05 or less was considered to show statistical significance.

Supporting Information {#sec020}
======================

###### Odds ratios (ORs) for each two-locus genotype for GWAS SNPs rs2106261 and rs2200733 involved in the pathogenesis of AF before adjustment for covariates.

For two SNPs, there are a total of 9 genotypes. The wild type or non-risk GGCC genotype was used as the reference and ORs for other genotypes were estimated against the reference genotype using Pearson's 2×2 contingency table χ^2^ tests using SPSS17.0. A. Analysis of ORs in the Discovery population. B. Analysis of ORs in the Replication I population. C. Analysis of ORs in the Replication II population. D. Analysis of ORs in the combined population with the Discovery, Replication I and Replication II cohorts. \**P*\<0.01.
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